How bacteraemia is reviewed by medicines licensing authorities in Europe

International Journal of Antimicrobial Agents

Volumn 30, Issue SUPPL. 1, 2007, Pages 103-107

  Toivonen, Markku ^a  

^a NDA Regulatory Science Ltd   (United Kingdom)

Author keywords

Bacteraemia; Daptomycin; EMEA; Linezolid; Quinupristin dalfopristin; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; PENICILLIN G; TIGECYCLINE; VANCOMYCIN;

ARTICLE; BACTEREMIA; COMMUNITY ACQUIRED PNEUMONIA; DRUG APPROVAL; DRUG INDICATION; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG LABELING; EUROPE; HUMANS; LICENSURE;

EID: 34848884841     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.06.031     Document Type: Article

References (18)

1. Bearman G.M., and Wenzel R.P. Bacteremias: a leading cause of death. Arch Med Res 36 (2005) 646-659
2. Pittet D., Tarara D., and Wenzel R.P. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 275 (1994) 1598-1601
3. Vincent J.L., Bihari D.J., Suter P.M., et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274 (1995) 639-644
4. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in medical intensive care units in the United States: National Nosocomial Infections Surveillance System. Crit Care Med 27 (1999) 887-892
5. Zinner S.H. New pathogens in neutropenic patients with cancer: an update for the new millennium. Int J Antimicrob Agents 16 (2000) 97-101
6. Banerjee S.N., Emori T.G., Culver D.H., et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 91 (1991) 86S-89S
7. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-98.
8. Update C.D.C. Staphylococcus aureus with reduced susceptibility to vancomycin in United States. MMWR Morb Mortal Wkly Rep 46 (1997) 813-815
9. Osmon S., Ward S., Fraser V.J., and Kollef M.H. Hospital mortality in patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 125 (2004) 607-616
10. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. CPMP/EWP/558/95 rev 1. European Medicines Agency, April 22, 2004.
11. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. CPMP/EWP/2655/99. European Medicines Agency, July 27, 2000.
12. Bhavnani S.M., Passarell J.A., Owen J.S., Loutit J.S., Porter S.B., and Ambrose P.G. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 (2006) 994-1000
13. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteremia: pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005) 923-929
14. Khatib R., Johnson L.B., Fakih M.G., et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 38 (2006) 7-14
15. Chang F.Y., MacDonald B.B., Peacock Jr. J.E., et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 82 (2003) 322-332
16. Chang F.Y., Peacock Jr. J.E., Musher D.M., et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82 (2003) 333-339
17. Tygacil. European Public Assessment Report. European Medicines Agency, May 11, 2006.
18. Fowler Jr. V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665